Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel
BRCA2 mutations appear to be the key genetic marker predicting who benefits most from a new prostate cancer drug combination, refining treatment precision.
A subgroup analysis of the Phase III PROpel trial in metastatic castration-resistant prostate cancer found that BRCA2 mutations conferred the strongest benefit from olaparib plus abiraterone (rPFS HR 0.20, OS HR 0.20), while ATM and CDK12 mutations showed only numerical benefit. These results clarify BRCA2 as the dominant HRR mutation driving efficacy of this approved combination, directly informing precision patient selection.
What the study was
- Study design
- phase_iii_rct_subgroup_analysis
- Population
- HRR-mutated metastatic castration-resistant prostate cancer patients (PROpel trial)
- Category
- Genomics/Precision Medicine
- Maturity
- Potentially Practice-Changing
- Journal
- European Urology Oncology
Why it surfaced
Phase 3 RCT subgroup analysis (PROpel); Eur Urol Oncol; gene-level HRR breakdown directly informs precision patient selection for approved regimen; BRCA2 HR 0.20 for both rPFS and OS is clinically striking; important for precision oncology clinical practice
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.